Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02897063 · ClinicalTrials.gov registry record · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
A Phase 1 study of Parkinson Disease and Multiple System Atrophy, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT02897063: Recruiting Phase 1 study of Parkinson Disease and Multiple System Atrophy, sponsored by Vanderbilt University Medical Center.
NCT02897063 is a Phase 1 study of Parkinson Disease and Multiple System Atrophy that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 34 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02897063, a Phase 1 study of Parkinson Disease and Multiple System Atrophy, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about the effects of midodrine and droxidopa, two medications used for the treatment of orthostatic hypotension (low blood pressure on standing), on the veins of the abdomen of patients with autonomic failure. The study will be conducted at Vanderbilt University Medical Center, and consists of 2 parts: a screening and 2 testing days. The total length of the study will be about 5 days. About 34 participants will be screened for the study.
Primary Outcome
The primary outcome will be the percent change from supine in stroke volume during HUT
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Midodrine
- DRUG Droxidopa
Study Locations (1)
Tennessee
- Autonomic Dysfunction Center/ Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-09 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT02897063 shows while recruiting
NCT02897063 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 5 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02897063 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT02897063 about?
NCT02897063 is a clinical study titled "Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure". The purpose of this study is to learn more about the effects of midodrine and droxidopa, two medications used for the treatment of orthostatic hypotension (low blood pressure on standing), on the veins of the abdomen of patients with autonomic failure. The study will be conducted at Vanderbilt Unive...
What is the current status of trial NCT02897063?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2016-09. Estimated completion is 2026-12.
What conditions does trial NCT02897063 study?
This clinical trial studies the following conditions: Parkinson Disease, Multiple System Atrophy, Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure.
What interventions are being tested in trial NCT02897063?
The interventions under investigation include: Placebo (DRUG), Midodrine (DRUG), Droxidopa (DRUG).
Who is sponsoring clinical trial NCT02897063?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02897063 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02897063's enrollment target sits among peer trials
34 197th of 297 higher than 101 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
RECRUITING · Phase 1
-
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
RECRUITING · Phase 1
-
First-in-Human Single and Multiple Dose of HL-400
RECRUITING · Phase 1
-
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
RECRUITING · Phase 1
-
[18F]F-DOPA Imaging in Patients With Autonomic Failure
RECRUITING · Phase 1
-
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
- NCT04315233 · 34 participants · Phase 1
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia